The ability of dopamine (DA) receptor antagonists to disrupt anticipatory and consummately measures of sexual behavior displayed by male rats in bilevel chambers was investigated. In Experiment 1, systemic administration of haloperidol, pimozide, and the Dl antagonist SCH 23390 reduced the number of anticipatory level changes (LC) displayed during a 5-min period before the introduction of a sexually receptive female, increased the mount and intromission latencies (ML and IL), and decreased the number of intromissions before ejaculation (NI) and the total number of ejaculations (NE). The dosages of these drugs required to reduce the LC were lower than those required to increase the ML or IL. Clozapine and the D2 antagonist sulpiride reduced the LC and increased the IL at comparable dosages, although neither drug affected the NI or NE. High dosages of haloperidol, pimozide, and clozapine delayed or abolished level changing and the initiation of copulation. In Experiment 2, bilateral infusions of haloperidol into the nucleus accumbens reduced the LC but did not affect consummatory measures of copulation, whereas bilateral infusions into the dorsal striatum increased the NE. Midline infusions of haloperidol to the medial preoptic area (MPOA) produced nearly all the effects of systemic administration, including a reduced LC, increased ML and IL, a decreased NI, and a decreased NE. These results indicate that both anticipatory and consummatory measures of sexual behavior were disrupted by DA receptor antagonists; however, the measure of anticipatory sexual behavior was more sensitive to disruption than consummatory measures of copulation. DA in the nucleus accumbens and MPOA may be involved in the control of anticipatory sexual behavior, whereas in the MPOA it may also be involved in the initiation of copulation and copulatory rate.
orgasm in human males (Petrie, 1985) and disrupt the initiation and rate of copulation in sexually active male rats (Ahlenius & Larsson, 1984a; Malmnas, 1973; Tagliamonte et al., 1974) .
Recently, we compared the effects of different DA antagonists on the copulatory activity of intact, sexually active male rats (Pfaus & Phillips, 1989) . The typical neuroleptics haloperidol and pimozide increased the mount and intromission latencies, increased the postejaculatory intervals, and decreased the number of intromissions that preceded ejaculation. The atypical neuroleptic clozapine and the D2-selective antagonist sulpiride both increased the mount and intromission latencies but did not affect copulation once it was initiated. In contrast, the antiemetic agent metoclopramide decreased the number of intromissions but did not affect the initiation of copulation. These results suggest that the initiation and rate of copulation may be affected differentially by DA antagonists.
Although inferences about the role of DA in motivational aspects of male copulatory behavior can be made from the effects of DA antagonists, some of the effects are paradoxical. For example, the increased intromission latencies typically observed after treatment with DA antagonists can be interpreted as a disruption, whereas the decreased number of intromissions before ejaculation can be interpreted as a facilitation (e.g., Sachs & Barfield, 1976) . However, there is evidence that haloperidol decreases the number of penile erections that are displayed by intact male rats (Pehek, 727 Thompson, Eaton, Bazzett, , an effect that could explain both the increased intromission latency and the decreased number of intromissions. Although mount latencies may be a more appropriate measure of the motivation to initiate copulation, they can be confounded by several factors, including the female's level of sexual receptivity and proceptivity (e.g., Everitt, 1990) . Thus, it is difficult to determine the role of DA in the sexual motivation of male rats by examining consummatory measures of copulatory behavior alone.
A new form of anticipatory sexual behavior was recently characterized in male rats by Mendelson and Pfaus (1989) . This behavior, observed in the bilevel chambers that were designed by Mendelson and Gorzalka (1987) , appeared as high rates of level changing during the 5-min adaptation periods before the introduction of a sexually receptive female for a test of copulation. Given evidence that anticipatory or preparatory aspects of motivated behaviors are sensitive to treatments that disrupt central DA neurotransmission (e.g., Blackburn, Phillips, & Fibiger, 1987; Blackburn, Pfaus, & Phillips, 1991) , the present experiments examined the doseresponse effects of centrally active DA receptor antagonists on level changing and copulatory behavior in sexually active male rats.
Experiment 1: Effects of Systemic Administration of Dopamine Antagonists
The first experiment was conducted to replicate and extend our previous findings with DA antagonists (Pfaus & Phillips, 1989) . Accordingly, we examined the dose-response effects of systemic administration of the typical neuroleptics haloperidol and pimozide, the atypical ncuroleptic clozapine, the antiemetic agent metoclopramide, the Dl-selective antagonist SCH 23390, and the D2-selective atypical neuroleptic sulpiride on anticipatory and consummatory aspects of sexual behavior in sexually active male rats.
Method
Subjects. Female and male Long-Evans rats were obtained from Charles River Canada, Incorporated, St. Constant, Quebec, Canada. They were separated by sex and housed in groups of 6 in 18 x 25 * 65 cm wire-mesh cages in a colony room that was maintained on a reversed 12:12-hr light-dark cycle at approximately 21 °C. Food and water were always available in the home cages. The females were bilaterally ovariectomi/ed via lumbar incisions under sodium pentobarbital anesthesia (Somnotol, 40 mg/kg) at least 4 weeks before testing. Sexual receptivity was induced in the females by subcutaneous injections of estradiol benzoate (10 ^g) and progesterone (500 Mg) 48 hr and 4 hr, respectively, before each test in which they participated as stimulus females.
Drug preparations. Haloperidol (McNeil) was dissolved in distilled water with a few drops of dilute glacial acetic acid to obtain concentrations of 0,0.05,0.1, 0.2, and 0.5 mg/ml. Pimozide (McNeil) was dissolved in distilled water that contained 0.1N HC1 and brought topH6 with 0.01 NNaOH to obtain concentrations of 0, 0.1, 0.5, 1, and 5 mg/ml. Clozapine (Sandoz) was dissolved in distilled water that contained 0.1 N HC1 and brought to pH 6 with 0.01 N NaOH to obtain concentrations of 0, 0.1, 0.5, 1, and 5 mg/ml. Metoclopramide hydrochloride (Sigma) was dissolved in distilled water with a few drops of dilute glacial acetic acid to obtain concentrations of 0, 0.1, 0.5, 1, and 5 mg/ml. The selective Dl receptor antagonist SCH 23390 hydrochloride (Schering) was dissolved in distilled water to obtain concentrations of 0, 0.01, 0.05, 0.1, and 0.5 mg/ml. The selective D2 receptor antagonist sulpiride (Sigma) was dissolved in distilled water that contained 0.1 N HC1 and brought to pH 6 with 0.01 N NaOH to obtain concentrations of 0, 0.5, 1, 5, and 10 mg/ ml. Ail drugs were injected in a volume of 1 ml/kg body weight. Dosages of haloperidol, pimozide, metoclopramide, SCH 23390, and sulpiride were injected 1 hr before testing, whereas dosages of pimozide were injected 4 hr before testing. The vehicle solution served as the control for each drug dosage.
Procedure. A total of 300 male rats (450-700 g) were given 10 baseline tests of sexual behavior before the experiments. The tests were 25 min in duration and conducted once every 4 days during the middle third of the dark cycle. During the tests, each male was placed into a bilevel chamber for a 5-min test of level changing after which a sexually receptive female was placed into the chamber for 20 min (see e.g., Pfaus, Mendelson, & Phillips, 1990 ). The occurrence of each level change, mount, intromission, and ejaculation was recorded on a computerized event recorder that derived the following anticipatory and consummatory measures of sexual behavior: (a) the number of level changes (LC) in the 5-min period, (b) the latency in seconds to initiate level changes (LCL), (c) mount and (d) intromission latencies (ML and 1L; time from the introduction of the female to the first mount or intromission in seconds), (e) the ejaculation latency (EL; time from the first intromission to the first ejaculation in seconds), (f) the postejaculatory interval (PEI; time from the first ejaculation to the next intromission in seconds), (g) the number of mounts (NM) and (h) the number of intromissions (NI) before the first ejaculation, (i) the interintromission interval (III; the ejaculation latency divided by the number of intromissions), (j) the intromission ratio (IR; number of mounts with intromission divided by the number of mounts with and without intromission), and (k) the total number of ejaculations achieved in the 20-min test (NE). In addition, the percentage of males that displayed level changes, mounts, intromissions, and ejaculations was recorded. By the 10th baseline test, all males had reached the criteria for inclusion: stable rates of level changing during the 5-min adaptation period, intromission within 5 min of the presentation of the female, ejaculation within 15 min of the first intromission, and the reinitiation of intromission within 10 min of ejaculation, on each of the last 3 baseline tests.
After the last baseline test, the rats were assigned randomly to one of the six drug groups (« = 50 per group). Within each group, 10 rats were assigned randomly to one of the five dosages of the drug and received two drug tests, the assigned dosage or the control solution, in a randomized order at 4-day intervals. Experimental tests began 4 days after the last baseline test and were conducted identically to it.
Statistical analyses. The effects of different dosages of each drug on the 11 measures of sexual behavior were compared statistically using the data of those rats in each group that displayed the sexual behavior under analysis; no arbitrary scores were assigned. When appropriate, the significance of the differences in the proportion of rats in each drug-dose condition that displayed mounts, intromissions, or ejaculations was assessed using chi-square tests (p < .05, two-tailed). The 11 measures of sexual behavior within each drug group were subjected to multiple one-way analyses of covariance (ANCOVAs) across different doses, with the control measures serving as the covariates for the respective drug dose measures. This procedure allowed animals to be used as their own controls and provided a true index of change for the effects of each dosage on each measure of sexual behavior. Because we have previously found significant correlations among consummatory measures of copula- lory behavior in the bilevel chambers (Pfaus, Mendelson, & Phillips, 1990) , the ANCOVAs that were conducted on these measures were corrected for elevated experiment-wise error using the Bonferroni method (Overall & Rhodes, 1987) . The adjusted Bonferroni alpha for each ANCOVA was p < .005. For each significant ANCOVA, post hoc pairwise comparisons of each dosage were made using the Tukey method.
Results

Haloperidol.
The highest dosage of haloperidol (0.5 mg/ kg) significantly reduced the percentage of rats that displayed levelchanges(to40%),tf (l,N-20 (Figure 1 ). The ANCOVA also detected an effect of haloperidol on the ML, F(3, 35) = 3.99, p < .01; the III, F(3, 34) = 3.51, p < .03; and the IR, F(3, 35) = 3.72, p < .02; however, these effects did not reach the level of significance required by the Bonferroni correction. Haloperidol had no significant overall effect on other measures of sexual behavior. Post hoc comparisons of the effect of each dosage revealed that 0.1 and 0.2 mg/kg significantly reduced the LC compared with the effects of the control solution or the lower dosage. The effect of 0.2 mg/kg on the LC was also significantly greater than the effect of 0.1 mg/ kg. In contrast, only 0.2 mg/kg significantly increased the IL and PEI and reduced the NI and NE compared with the effects of the control solution and the two lower dosages.
Pimozide. The effects of pimozide were very similar to those of haloperidol. The highest dosage (5.0 mg/kg) significantly decreased the proportion of rats that displayed level changes (to 50%), Figure 2) ; and the III, F(3, 30) = 5.77, p < .004. The ANCOVA also detected an effect of pimozide on the EL, F(3, 30) = 4.89, p < .007. but this effect did not reach the level of significance required by the Bonferroni correction. Pimozide had no significant effect on other measures of sexual behavior. Post hoc comparisons of the effect of each dosage revealed that 0.5 and 1.0 mg/kg significantly reduced the LC compared with the effect of the control solution. All dosages of pimozide significantly reduced the NE from the control value, whereas only 1.0 mg/kg significantly increased the IL, PEI, and III and decreased the NI compared with the effects of the control solution.
Clozapine. None of the rats that were treated with 5.0 mg/kg clozapine initiated copulatory behavior, although 9 of the 10 rats displayed level changing. The 1.0 mg/kg dosage also significantly decreased the proportion of rats that displayed mounts (to 30%), did not affect the proportion of rats that displayed level changing. The rats that were treated with the two highest dosages of clozapine appeared less sedated than the rats that were treated with the highest dosage of haloperidol or pimozide. Most of these rats moved about freely in the chambers, and all displayed periods of anogenital investigation of the receptive females. Because the percentage of rats that engaged in copulatory behavior was significantly lower in these two dosage groups, the measures of copulatory behavior from these rats were not subjected further to statistical analysis. However, because the proportion of rats that displayed level changing was not significantly different in these groups, level changing data from all groups were subjected to the ANCOVA. In rats that displayed measures of sexual behavior, the ANCOVA detected a significant overall effect of clozapine on the LC, F(4, 44) = 22.04, p < .00001 ( Figure 3 ). The ANCOVA also detected an effect of clozapine on the ML, F(2, 26) = 3.98, p < .03; the IL, F(2, 26) = 3.87, p < .03; and the NE, F(2, 25) = 5.00, p < .01, although these effects did not reach the level of significance required by the Bon- ferroni correction. Clozapine had no effect on other measures of sexual behavior. Post hoc comparisons of the effect of each dosage revealed that 0.5, 1.0, and 5.0 mg/kg significantly reduced rates of the LC compared with the effect of the control solution. Treatment with the 5.0 mg/kg dosage reduced rates of the LC significantly from those obtained with the two lower dosages.
Metoclopramide. None of the dosages of metoclopramide decreased the proportion of rats that displayed level changing, mounts, intromissions, or ejaculations. The ANCOVA detected an effect of metoclopramide on the NI, ^(4, 44) = 3.22, p < .02; and the III, F(4, 44) = 3.23, p < .02 ( Figure  4) ; however, neither of these effects reached the level of significance required by the Bonferroni correction.
SCH23390. Although 0.5 mg/kg SCH 23390 decreased the proportion of rats that displayed level changes (to 70%), mounts (to 70%), intromissions (to 70%), and ejaculations (to 60%), these effects did not reach statistical significance. The ANCOVA detected significant overall effects of SCH 23390 on the LC, F(4, 44) = 55.01, p < .00001; the ML, F(4, 41) = 12.62, p < .0001; the IL, F(4, 41) = 13.51 p < .0001; and the PEI, F(4, 39) -6.43, p < .0007 ( Figure 5 ). The ANCOVA also detected an overall effect of SCH 23390 on the NI, F(4,41) = 3.27, p < .02; the NE, F(4, 39) = 2.95, p < .03; and the III, F(4, 39) = 2.92, p < .03; however, these effects did not reach the level of significance required by the Bonferroni correction. Despite the fact that SCH 23390 increased the LCL and produced a large degree of variation in the EL, the ANCOVA did not detect overall significant effects for these measures of sexual behavior. Post hoc comparisons revealed that all dosages of SCH 23390 significantly reduced the LC compared with the effect of the control solution. The effect of all dosages of SCH 23390 on the LC were also significantly different from one another. In contrast, only 0.5 mg/kg significantly increased the ML, IL, and PEI compared with the effects of the control solution and the lower dosages.
Sulpiride. None of the dosages of sulphide decreased the proportion of rats that displayed level changes, mounts, intromissions, or ejaculations. The ANCOVA detected a significant overall effect of sulphide on the LC, F(4,44) = 6.56, p < .0005. Although the ANCOVA detected an overall effect of sulpiride on the IL, F(4, 44) = 2.92, p < .03, this effect did not reach the level of significance required by the Bonferroni correction. None of the other measures of sexual behavior were affected significantly by sulpiride ( Figure 6 ). Post hoc comparisons of the effect of each dosage revealed that These results confirm our previous findings that DA antagonists differentially affect the copulatory behavior of intact, sexually active male rats (Pfaus & Phillips, 1989 ) and extend those findings to level changing, a form of anticipatory sexual behavior that is observed in bilevel chambers. The typical neuroleptics haloperidol and pimozide decreased the LC in the 5-min period that preceded the introduction of a sexually receptive female, increased the IL, and decreased the Nl. High doses of these drugs abolished level changing and copulatory behavior in most of the rats. Similarly, the atypical neuroleptic clozapine and the D2-selective atypical neuroleptic sulphide both decreased the LC and increased the IL, although the effects on the IL did not reach the level of significance required by the Bonferroni correction. However, neither drug affected the NI. High doses of clozapine abolished copulatory behavior but not level changing. The Dl-selective antagonist SCH 23390 decreased the LC, increased the ML and the IL, and produced a trend toward a decreased NI. Finally, although metoclopramide did not affect any measure of anticipatory or consummatory sexual behavior significantly, it produced a trend toward a decreased NI. Thus, typical and atypical neuroleptics delay or abolish both level changing and the initiation of mounts with intromission, whereas these drugs differentially reduced the NI and the NE.
Several of these results are inconsistent with previous reports. First, substantial increases in the PEI have been reported after treatment with moderate dosages of haloperidol or pimozide (Ahlenius & Larsson, 1984a , 1984b Mclntosh & Barfield, 1984) . Although moderate dosages of haloperidol and pimozide increased the PEI in the present experiment, only the effect of pimozide reached the level of statistical significance required by the Bonferroni correction. However, in our previous study, the effect of pimozide on the PEI was of marginal significance (Pfaus & Phillips, 1989) . Similarly, pimozide has been reported to decrease the EL (Mclntosh & Barfield, 1984) . However, in the present experiment and a previous study (Pfaus & Phillips, 1989) we failed to observe a decrease in the EL after pimozide treatment. In that previous study, sulphide significantly increased the IL, and metoclopramide significantly reduced the NI. Although these effects were detected in the present experiment, they did not reach the level of significance required by the Bonferroni correction. These discrepancies likely resulted from a combination of different methodological procedures, including the use of different testing chambers, animals with different baselines of sexual behavior, and the use of a conservative statistical procedure (the Bonferroni method) to correct for the elevated experiment-wise error that occurs when related measures are assessed independently. It is interesting to note that haloperidol, pimozide, clozapine, sulphide, and SCH 23390 significantly decreased the LC at doses that did not significantly increase the LCL and that, with few exceptions, did not significantly affect measures of copulatory behavior. This indicates that the disruption of level changing was not secondary to a general motor impairment and that level changing was more sensitive to disruption by DA antagonists than traditional, copulatorybased measures of sexual motivation (e.g., ML, IL, or NI). It is interesting to note that instrumental responding by male rats for a secondary sexual reinforcer has been disrupted by the mixed D1-D2 receptor antagonist a-flupenthixol at doses that do not affect the ML or IL (Everitt, 1990; Robbins, Cador, Taylor, & Everitt, 1989) .
These results also indicate that the relatively selective antagonism of Dl and D2 receptors has similar effects on the anticipation and initiation of male sexual behavior. Both the Dl-selective antagonist SCH 23390 and the D2-selective antagonist sulpiride, when administered alone, decreased the LC and increased IL, although the effect of sulpiride on the IL was of marginal significance. SCH 23390 also produced a trend toward a decreased NI. Haloperidol and pimozide, both of which possess a greater affinity for D2 than Dl receptors (Tamminga & Gerlach, 1987) , had effects that were nearly identical to SCH 23390. This is consistent with reports of similar actions of Dl-and D2-selective compounds in male sexual behavior (Ahlenius & Larsson, 1990) , in the agonist-induced inhibition of single unit activity in the nucleus accumbens, globus pallidus, and substantia nigra pars reticulata (Carlson, Bergstrom, Demo, & Walters, 1988; Walters, Bergstrom, Carlson, Chase, & Braun, 1987; Weick & Walters, 1987; White & Wang, 1986) , in the display of stereotypies (Ami, Hyttel, & Perregaard, 1987; Mashurano & Waddington, 1986 ) and turning after unilateral mesostriatal lesions (Robertson & Robertson, 1986) , and in the yawning and penile erection syndrome (Melis, Argiolas, & Gessa, 1987) .
Finally, we note that many typical and atypical neuroleptics bind to 5-HT2, al, and HI receptors (Seeman & Grigoriadis, 1987; Tamminga & Gerlach, 1987) , and some atypical neuroleptics also possess anticholinergic activity (Snyder, Banerjee, Yamamura, & Greenberg, 1974) . It is thus conceivable that neuroleptic drugs could act at nondopaminergic sites to affect certain aspects of masculine sexual behavior. This tentative hypothesis is supported by evidence that the relatively selective al antagonist prazosin or the relatively selective 5-HT2 antagonist pirenperone both increase the ML and IL (Clark, Smith, & Davidson, 1985 : Mendelson & Gorzalka, 1985 . In addition, pirenperone, like haloperidol, pimozide, and SCH 23390, also decreases the NI (Mendelson & Gorzalka, 1985) . However, the fact that these drugs exert a similar influence on male copulatory behavior does not necessarily mean that they work via a single neurotransmitter system. It is possible that considerable overlap exists in the control of masculine sexual behavior by monoamines and their receptor subtypes, for example, by acting through common neuronal second messenger systems in certain brain areas.
Experiment 2: Effects of Central Infusions of
Haloperidol
It is currently unclear where DA antagonists act to disrupt male sexual behavior. Although a peripheral effect is unlikely, given that the peripherally active DA antagonist domperidone has no effect on the copulatory behavior or penile reflexes of intact, sexually active rats (Falaschi et al., 1981; Pehek, Thompson, Eaton, Bazzett, & Hull, 1988) , the central sites for the actions of DA antagonists on male sexual behavior have not been studied extensively. To date, the effects of DA antagonists have been examined in diencephalic DA terminals in the medial preoptic area (MPOA) and in mesolimbic DA terminals in the nucleus accumbens.
Hull and colleagues were the first to report a disruptive effect of a DA antagonist on male copulatory behavior after central infusion into the MPOA (Pehek, Warner et al., 1988) . In that study, midline infusions of the mixed D1-D2 antagonist c/s-flupenthixol (20 and 40 ng) to sexually active male rats significantly reduced the proportion of rats that mounted, intromitted, or ejaculated. In rats that initiated copulation, both doses of cw-flupenthixol significantly decreased the total number of ejaculations and increased the III. These doses also increased the EL, although that effect reached statistical significance only after infusion of the 20-^g dose. In a subsequent study , infusions of the D1 -selective antagonist SCH 23390 (10 mg) to the MPOA increased both the ML and IL and decreased the NI. These effects were nearly identical to those obtained in the previous experiment after systemic administration of SCH 23390. However, infusions of the D2-selective agonist LY 163502 to the MPOA also increased the ML and IL and decreased the MI, suggesting that Dl and D2 receptors in the MPOA might have opposite effects on the initiation and rate of copulation. Everitt (1990) reported that bilateral infusions of the D2-selective antagonist raclopride (5 ^g) to the nucleus accumbens had no effect on the ML or IL of sexually active male rats paired with normally estrous females. However, if those males were paired with estrous females that had received prior injections of a-flupenthixol (to abolish preceptive behaviors), then the infusions of raclopride markedly increased both the ML and IL. Interestingly, although unilateral infusions of the DA receptor agonist apomorphine to either the nucleus accumbens or the dorsal striatum do not significantly affect copulatory behavior (Hull et al., 1986) , bilateral infusions of d-amphetamine (1 #g) to the nucleus accumbens significantly reduce the ML and IL of intact, sexually active male rats and restore instrumental responding for a secondary sexual reinforcer in male rats with excitotoxic lesions of the basolateral amygdala .
Together, these studies suggest that DA transmission in the MPOA and nucleus accumbens may be important for the expression of copulatory behavior in male rats. Indeed, in vivo voltammetry and microdialysis studies confirm an increase in DA and catecholamine transmission in both the nucleus accumbens and MPOA, respectively, during copulatory activity in male rats (Mas, Gonzalez-Mora, Louilot, Sole, & Guadelupe, 1990; Pfaus, Damsma et al., 1990; Phillips, Pfaus, & Blaha, 1991; Pleim, Matochik, Barfield, & Auerbach, 1990) . To further evaluate the role of mesolimbic, mesostriatal, and diencephalic DA terminals in anticipatory and consummatory aspects of sexual behavior in the male rat, we examined the ability of different doses of haloperidol to disrupt sexual behavior after bilateral infusions into either the nucleus accumbens or striatum or after midline infusions into the MPOA.
Method
Subjects and surgery. Thirty male Long-Evans rats (300-400 g) were obtained from Charles River Canada, Incorporated, St. Constant, Quebec, Canada, and housed as in Experiment 1. The stimulus females that participated in Experiment 1 also participated in this experiment. Sexual receptivity was induced in the females as in Experiment 1.
The males were given 10 baseline tests of sexual behavior in the bilevel chambers before cannula implantation. All tests were conducted at 4-day intervals, as described in Experiment 1, and all rats achieved the same standard criteria for inclusion.
Twenty rats were then implanted bilaterally with 23-gauge stainless-steel guide cannulae (Plastics One, Roanoke, VA) that were aimed at either the nucleus accumbens (n = 10) or the anteriodorsal striatum (« = 10); 10 rats each received a single midline 23-gauge stainless-steel guide cannula that was aimed at the MPOA. All surgery was performed while the rats were under sodium pentobarbital anesthesia (Somnotol, 60 mg/kg), using a Kopf stereotaxic frame. Briefly, the scalp was cut and retracted, and four small screws were inserted into the skull. Small burr holes were drilled into the skull above the mediolateral coordinates for each region, and the guide cannula was lowered to the appropriate depth. The guide cannula was anchored to the skull screws with dental cement that surrounded both the screws and cannula. Rats received bilateral cannula implants to the nucleus accumbens (AP =1.7 mm, ML = 3.0 mm, DV = -6.5 mm from the surface of the brain, with the ML coordinates offset 14° laterally) or the striatum (AP = 0.7 mm, ML = 2.6 mm, DV = -4.0 mm from the surface of the brain) according to the atlas of Paxinos and Watson (1982) . The other rats received a single midline cannula implant to the MPOA (AP = 2.4 mm, ML = 0.2 mm, DV = -7.0 mm from the surface of the brain) according to the atlas of Pellegrino, Pellegrino, and Cushman (1979) . The midline cannula implantation to the MPOA was chosen to replicate the method and coordinates reported by Pehek, Warner et al. (1988) . To protect each guide cannula when not in use, a 27-gauge stainlesssteel dummy cannula (Plastics One, Roanoke, VA), slightly longer than the guide cannula, was inserted. After surgery, the males were housed individually in 44 x 21 x 23 cm plastic tubs. They were allowed 1 week of recovery before experimental testing.
Postsurgical behavioral testing. The males were given six postsurgical tests of sexual behavior that were conducted identically to their baseline tests. During the first two tests, the males received microinfusions of the vehicle solution 5 min before being placed in one of the bilevel chambers. Microinfusions were made by replacing the dummy cannula with an injection cannula that protruded 0.5 mm from the ventral end of the guide cannula. The infusion cannula was left in place for 45 s after each infusion to minimize the diffusion of solution back up the internal shaft of the guide cannula. After the infusions, each male was placed in one of the bilevel chambers for a 5-min test of level changing, after which a sexually receptive female was placed in the chamber for a 20-min test of copulation. All 30 males displayed normal rates of level changing and copulatory behavior during these first two postsurgical tests.
During the four subsequent tests of sexual behavior, the males received three doses of haloperidol or the vehicle, which were administered in a latinized design, 5 min before each test. Males with bilateral cannula placements to the nucleus accumbens or striatum received infusions of 0, 1, 5, and 10 *»g/side of haloperidol, whereas males with midline cannula placements to the MPOA received infusions of 0, 2, 10, and 20 ng of haloperidol.
Drug administration. Haloperidol (McNeil) was dissolved in distilled water with a few drops of 0.1% glacial acetic acid to obtain concentrations of 0, 1, 2, 5, 10, and 20 /*gVl (pH s 5.5). Doses of haloperidol were administered in a constant volume of 1 iil/cannula. All infusions were made using an electrically driven infusion pump (Sage Instruments Model 3H1A) at a rate of 1 /il/min. The vehicle solution served as the control.
Histology. After the drug tests, the males were anesthetized with sodium pentobarbital (120 mg/kg ip) and decapitated; their brains were removed and stored in a 40% formalin-sucrose solution. The brains were subsequently frozen in a cryostat, and 40-nm sections were cut, mounted on gel-coated glass slides, and examined under a microscope. All of the males in each group had cannula tracks ending in their respective target structures. Cannula placements are shown in Figure 7 .
Statistical analyses. As in the first experiment, the effects of different doses of haloperidol on measures of anticipatory and consummatory sexual behavior were compared statistically using the data of those rats in each group that displayed the sexual behavior under analysis: no arbitrary scores were assigned. The 11 measures of sexual behavior were subjected to multiple within-subjects analyses of variance (ANOVAs) 
Results
Nucleus accumbens. None of the doses of haloperidol decreased the proportion of rats that displayed level changing, mounts, intromissions, or ejaculations. The ANOVA detected a significant overall effect of haloperidol on the LC, F(3,27) = 10.19, p < .00026 (Figure 8 ), but not on any other measure of sexual behavior. Post hoc comparisons revealed that the highest dose, 10 Mg/side, significantly reduced the LC compared with the effect of the control solution or the lower doses.
Dorsal striatum. None of the doses of haloperidol decreased the proportion of rats that displayed level changing, mounts, intromissions, or ejaculations. The ANOVA detected a significant overall effect of haloperidol on the NE, F(3, 27) = 5.45, p < .005 (Figure 9 ), but not on any other measure of sexual behavior. Post hoc comparisons revealed that the highest dose, 10 /*g/side, significantly increased the NE compared with the effect of the control solution or the lower doses.
Medial preoptic area. None of the doses of haloperidol decreased the proportion of rats that displayed level changing, mounts, or intromissions. Only one rat that received the highest dose (20 ng) failed to ejaculate. The effects of haloperidol infusions into the MPOA (Figure 10) were strikingly similar to those of systemic administration in Experiment 1. The ANOVA detected significant overall effects of haloperidol on the LC, F(3, 27) = 53.53,^ < .0001; the LCL, F(3, 27) = 5.57, p < .005; the IL, F(3, 27) = 12.48, p < .0001; the NI, F(3, 27) = 7.86, p < .0009; the NE, F(3, 27) = 5.62, p < .005; and the IR, F(3, 27) = 9.75, p < .0003. Although the ANOVA detected an effect of haloperidol on the ML, F(3, 27) = 4.59, p < .02, this effect did not reach the level of significance required by the Bonferroni correction. Post hoc comparisons of the effect of each dose revealed that both the 10-and 20-jig doses significantly reduced the LC, increased the IL, and decreased the NI compared with the effects of the control solution and the lower dose, whereas only the 20-jig dose significantly increased the LCL and decreased the NE and IR, compared with the effects of the control solution and the lower doses.
Interestingly, only 3 of the males that received the 10-,ug dose pursued the female from level to level during bouts of copulation, whereas none of the males that received the 20-Mg dose pursued the female. Those rats typically remained on the bottom level throughout the 20-min test, although all oriented toward the female as she moved from the top level to the bottom. This result could be taken as evidence of a general motor or sensory disruption; however, the fact that haloperidol did not significantly increase the EL or III indicates that most of the rats were capable of completing the first copulatory series in a normal amount of time. Thus, haloperidol infusions to the MPOA may have diminished a little-used measure of consummatory sexual behavior in the bilevel chambers: pursuit of the female.
Discussion
This experiment provides the first demonstration that the DA receptor antagonist haloperidol affects anticipatory and consummatory aspects of male sexual behavior differently in different DA terminal regions. Bilateral infusions of haloperidol into the nucleus accumbens, a major terminal of the mesolimbic A10 DA pathway (Lindvall, 1979) , attenuated level changing without significantly affecting consummatory measures of copulatory behavior. In contrast, bilateral infusions of haloperidol into the dorsal striatum, a major terminal of the mesostriatal A9 DA pathway (Lindvall, 1979) , increased the NE displayed during the 20-min test. Finally, midline infusions of haloperidol into the MPOA, a major terminal of the incertohypothalamic A14 DA pathway (Lindvall, 1979; Moore, 1987) , produced nearly all of the effects of systemic administration, including a decrease in the LC, an increase in the IL, and decreases in the NI and NE.
The effect of haloperidol infusions into the MPOA are consistent with previous reports that single midline infusions of the mixed D1-D2 antagonist cw-flupenthixol or the Dlselective antagonist SCH 23390 to similar coordinates in the MPOA disrupt the initiation and rate of copulation in male rats Pehek, Warner et al., 1988) . The lack of effect of haloperidol infusions into the nucleus accumbens on copulation is also consistent with the lack of effect of intraaccumbens infusions of the D2-selective antagonist raclopride on copulation (Everitt, 1990) . The increase in NE that was produced by haloperidol infusions into the anteriodorsal striatum was unexpected because the systemic administration of haloperidol decreased, rather than increased, the NE in Experiment 1. However, this result may have been more apparent than real because the highest dose of haloperidol induced a large but nonsignificant decrease in the ELs, an effect that could easily increase the NE in a fixed time period.
Although the effects of haloperidol infusions into the MPOA or nucleus accumbens on male sexual behavior are generally consistent with the results of previous studies, they are difficult to interpret without an examination of the effects of infusions into nearby brain sites or other DA terminals. Centrally infused drugs can spread in many directions from the tip of a cannula. We have subsequently observed that 1 nl cresyl violet that is infused into the nucleus accumbens is restricted to an area of approximately 1-2 mm 3 in the 1st
hour after the infusion (Pfaus, Kaplitt, & Pfaff, 1991) . However, the spread of cresyl violet away from a cannula tip cannot be used to infer the spread of a drug to its binding sites. Indeed, infusion of [ 3 H]dopamine (100 iug/Vl) into the dorsal striatum has been shown to diffuse in gradations away from the infusion site (Jackson & Kelly, 1983) . In that study, cannula tracks terminated in the caudate nucleus 2-3 mm away from the nucleus accumbens and 5 mm away from the olfactory tubercle. Solution binding analyses revealed that 1 hr after infusion the nucleus accumbens displayed approximately 11% of the radioactivity (disintegrations per minute) found in the caudate, whereas the olfactory tubercle displayed approximately 0.2% of the radioactivity.
Any diffusion becomes a potential problem when interpreting the effects of central infusions of haloperidol, especially infusions made into structures that are relatively close to one another, such as the nucleus accumbens and MPOA. For example, it cannot be determined unequivocally whether the decreased LC that was produced by infusions of haloperidol into the nucleus accumbens were due to a specific action in that site or whether it resulted from the spread to adjacent areas such as the diagonal band, medial or lateral septal nuclei, ventral pallidum, or even the MPOA. However, it is unlikely that the effect of accumbens infusions were due to an effect in the MPOA because most of the cannula tracks in the accumbens terminated in sites over 1 mm from the MPOA (Figure 7) . If the spread of the highest dose of haloperidol (10 ,ug/side) approximates 10% of the spread of 100 Mg/nl [ 3 H]dopamine (because 100 Mg/A«l of DA is a 650 mM concentration, whereas 10 jig//J-side ' of haloperidol is a total concentration of 53.3 mM), then a liberal estimate of the actual amount of haloperidol reaching the MPOA within an hour of infusion would be approximately 2 ^g, a dose that is not sufficient to affect level changing after infusion into the MPOA. Regarding midline infusions into the MPOA, it is conceivable that haloperidol could have diffused into the third ventricle and acted at undetermined sites to produce its effects. However, this is also unlikely given that intracerebroventricular infusions of DA antagonists do not affect the sexual behavior of male rats (Pehek, Warner et al., 1988) . Nevertheless, the results of this experiment should be con- sidered preliminary until the effects of haloperidol infusions into the appropriate control sites are examined.
General Discussion
These results have several important implications for the role of DA in male sexual behavior. First, it is apparent that anticipatory measures of sexual behavior are more sensitive to disruption by systemically administered DA antagonists than are consummatory measures of copulation. This is consistent with data from the feeding and avoidance literatures suggesting that anticipatory or preparatory behaviors, such as hoarding or instrumental responding, are more sensitive than consummatory measures, such as feeding or escape, to the disruptive effects of DA antagonists (Blackburn & Phillips, 1990a , 1990b Blackburn et al., 1987; Tombaugh, Tombaugh, & Anisman, 1979) . The fact that a measure of anticipatory sexual behavior can be dissociated with low doses of DA antagonists from the initiation of copulation also adds support to our previous finding that these measures are statistically independent (Pfaus, Mendelson, & Phillips, 1990) . Finally, these results are also consistent with clinical evidence that disorders of sexual desire, arousal, and orgasm are associated with DA antagonist treatment in human males (Petrie, 1985) . To the extent that the anticipation and initiation of sexual activity in male rats are analogous to sexual desire and arousal, respectively, in human males (American Psychiatric Association, 1987; Pfaus, Mendelson, & Phillips, 1990) , we would predict that sexual desire might be more susceptible to disruption by low doses of DA antagonists than sexual arousal or orgasm.
The systemic administration of DA antagonists results in binding of those drugs to many DA terminal regions in the brain. Although it was not the purpose of Experiment 2 to provide an exhaustive account of the role of DA terminal regions in male sexual behavior, the results tentatively suggest that diencephalic, mesolimbic, and mesostriatal DA terminal regions contribute differentially to the control of male sexual behavior. Infusions of haloperidol into the MPOA produced nearly all of the effects of systemic administration, including disruption of anticipatory behavior, copulatory initiation, rate, and hit rate (as defined in Sachs, 1978; Pfaus, Mendelson, & Phillips, 1990) . Those effects are consistent with a substantial body of evidence that electrolytic or neurotoxic lesions of the MPOA disrupt or eliminate copulatory activity (e.g., Hansen, Kohler, & Ross, 1982; Heimer & Larsson, 1966 -1967 van de Poll & van Dis, 1979) . However, it is less clear why infusions of haloperidol into the MPOA should also disrupt level changing. One possibility is that the anticipatory behavior that is assessed by level changing is dependent on olfactory cues present in the chambers from previous tests. In rodents, the MPOA receives a large efferent projection from the corticomedial amygdala via the stria terminalis (Lehman, Winans, & Powers, 1980) . The corticomedial amygdala, in turn, receives efferents from the vomeronasal organ and olfactory bulbs (Davis, Macrides, Young, Schneider, & Rosene, 1978; Scalia & Winans, 1975) . Olfactory stimuli from a sexually receptive female rat can evoke electrical activity in the MPOA of intact but not castrated male rats (Pfaff & Pfaffmann, 1969) . Thus, the MPOA may process olfactory information that is important for some forms of anticipatory sexual behavior in male rats. This suggestion is consistent with evidence that electrolytic lesions of the MPOA decrease the preference of male rats for sexually receptive female rats (Edwards & Einhorn, 1986) .
In light of evidence that infusions of either apomorphine or OT-flupenthixol to the MPOA selectively affects the parasympathetic activation of penile erection (Pehek, Thompson, & Hull, 1989) , it is possible that the increased ILs and decreased NIs after systemic administration of DA antagonists might reflect the antagonism of DA receptors in the MPOA that control erection. It is tempting to speculate that DA in the MPOA may thus serve as an interface between olfactory sexual cues and steroid-regulated autonomic processes that drive penile erections. However, activation of the MPOA by olfactory sexual cues might not be limited to the activation of autonomic processes but might also increase activity in the medial forebrain bundle which, in turn, should lead to the activation of DA neurons in the ventral tegmental area (VTA). Thus, olfactory sexual cues could activate diencephalic and mesolimbic DA systems concurrently to facilitate erection and anticipatory motor responses. Using in vivo voltammetry, we have recently observed that DA and catecholamine oxidation currents increase immediately and significantly in the nucleus accumbens and MPOA, respectively, of sexually active male rats that are presented with either a sexually receptive female or a slide containing estrous vaginal secretions behind a wire-mesh screen (Pfaus, 1990; Phillips et al., 1991) . Interestingly, although both stimuli increased the DA oxidation signals significantly in the nucleus accumbens, the magnitude of the signal during the presentation of the female was almost three times greater than that observed during the presentation of the estrous secretions. In contrast, the magnitude of the catecholamine oxidation signals in the MPOA was nearly identical during the presentation of these stimuli. Hull et al. (1989) proposed that Dl and D2 receptors in the MPOA may have opposing actions on male copulatory behavior, based on the finding that both the Dl-selective antagonist SCH 23390 and the D2-selective agonist LY 163502 increased the ML and IL and decreased the NE. Given that haloperidol binds predominantly to D2 receptors (Seeman & Grigoriadis, 1987; Tamminga & Gerlach, 1987) , the results of Experiment 2 do not support a differential role of Dl and D2 receptors in the MPOA in the control of copulatory behavior in male rats, although a differential effect on penile reflexes cannot be ruled out.
As with the MPOA, haloperidol infusions into the nucleus accumbens significantly decreased the LC. However, such infusions did not significantly affect consummately measures of copulation, suggesting that DA terminals in the nucleus accumbens may play a relatively selective role in the control of anticipatory sexual behavior. This is consistent with a large body of evidence implicating DA terminals in the nucleus accumbens in the control of preparatory-but not consummatory aspects of feeding behavior (e.g., Kelley & Stinus, 1985; Koob, Riley, Smith, & Robbins, 1978) . However, electrolytic lesions of the A10 cell bodies in the VTA that produced an average 77% depletion of DA in the nucleus accumbens have been reported to increase MLs and ILs and PEIs in intact, sexually active rats (Brackett, luvone, & Edwards, 1986) . Similarly, bilateral 6-hydroxydopamine (6-OHDA) lesions of DA terminals in the nucleus accumbens have been reported to increase MLs in sexually active male rats . Moreover, in vivo voltammetry and microdialysis studies have demonstrated that DA transmission increases in the nucleus accumbens during copulatory activity in male rats (Mas et al., 1990; Pfaus, Damsma et al., 1990; Phillips et al., 1991; Pleim et al., 1990) . In particular, the use of chronoamperometry has revealed that DA oxidation signals in the nucleus accumbens increase both during the presentation of a sexually receptive female and further during the initiation of copulation . Thus, the apparent behavioral selectivity of haloperidol infusions into the nucleus accumbens on anticipatory sexual behavior in this study should be viewed with caution. Although haloperidol increased the NE after infusion of the highest dose to the dorsal striatum, this effect can be explained by the large but nonsignificant decreases in the ELs. Thus, it would appear that haloperidol had only marginal effects on copulatory behavior in the striatum. This is inconsistent with the results of Brackett et al. (1986) in which lesions of the A9 cell bodies in the substantia nigra pars compacta that produced an average 56% depletion of DA in the striatum were reported to increase the ML and IL, decrease the NI, and decrease the NE in sexually active rats. Bilateral 6-OHDA lesions of the striatum have also been reported to increase the ML and IL of sexually active rats but only if the stimulus females displayed preceptive behaviors during the test. Those lesions had no effect on the male's copulatory behavior if the stimulus females were treated with a-flupenthixol to eliminate preceptive behaviors. Interestingly, in vivo microdialysis demonstrated small but significant increases in DA transmission in the dorsal striatum during copulatory activity in male rats (Pfaus, Damsma et al., 1990) , although chronoamperometry revealed that DA oxidation currents increased progressively throughout a test of copulatory behavior and were not associated with any particular aspect of sexual activity . Moreover, the presentation of a sexually receptive female behind a screen did not affect striatal DA levels (Pfaus, Damsma et al., 1990; Phillips et al., 1991) , which is consistent with the lack of effect of haloperidol infusions on measures of anticipatory sexual behavior. Clearly, more research is required to specify the exact role of mesostriatal DA terminals in the sexual behavior of male rats.
Finally, although the present results tentatively suggest that haloperidol acts in the nucleus accumbens and MPOA to decrease anticipatory level changing and in the MPOA or other diencephalic structures to disrupt consummatory aspects of copulation, we cannot rule out the possibility that DA antagonists act at other DA terminal regions to affect sexual behavior in the male rat. In particular, both the corticomedial and basolateral amygdalae receive mesolimbic DA projections from the VTA (Fallen, Koziell, & Moore, 1978) . Bilateral electrolytic lesions of the medial nucleus of the amygdala eliminate anogenital investigation of receptive females and reduce the proportion of male hamsters that subsequently initiate copulatory activity (Lehman et al., 1980) . In addition, bilateral excitotoxic lesions of the basolateral amygdala reduce rates of instrumental responding in sexually active male rats for a secondary sexual reinforcer without affecting copulation . The olfactory tubercle also receives a major DA projection from the VTA (Roth, Wulf, & Deutsch, 1987) . Although electrolytic lesions of the olfactory tubercle do not affect copulatory behavior in male rats (Perkins, Perkins, & Hitt, 1980) , it would be important to examine whether DA antagonists or 6-OHDA lesions in this structure affect measures of anticipatory sexual behavior.
